Press Releases

Date Title and Summary Additional Formats
Toggle Summary Stereotaxis Submits 510(k) Application to FDA for Vdrive(TM) With V-CAS(TM) Catheter Advancement System
ST. LOUIS , June 10, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has submitted a 510(k) Premarket Notification to the Food and Drug Administration ( FDA ) for the Company's Vdrive™ Robotic Navigation System with V-CAS™ Catheter Advancement System.
View HTML
Toggle Summary Stereotaxis to Highlight Efficiency, Efficacy and Safety of Its Technology at Cardiostim 2014
ST. LOUIS , June 16, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will participate in Cardiostim 2014, the biennial scientific congress of the European Heart Rhythm Association (EHRA), to be held June 18-21, 2014 in Nice, France .
View HTML
Toggle Summary Stereotaxis to Present Niobe(R) System Technology at Japan Heart Rhythm Society
Represents Largest Japanese Audience for Company to Date ST. LOUIS , July 21, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will present at the 29 th Annual Meeting of the Japanese Heart Rhythm Society in Tokyo beginning July 23, 2014 .
View HTML
Toggle Summary Stereotaxis to Report Second Quarter 2014 Financial Results on August 4, 2014
ST. LOUIS , July 28, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2014 second quarter ended June 30, 2014 on Monday, August 4, 2014 after the close of the U.S. financial markets.
View HTML
Toggle Summary Stereotaxis Reports 2014 Second Quarter Financial Results
-Achieves Second Consecutive Quarter of Strong Recurring Revenue- -Improves Operating Loss by 16% from First Half of 2013- -Showcases Technologies at Preeminent Industry Events in Target Markets- -Launches Ablation History for Improved Electrophysiology Procedures- -Files FDA Application for
View HTML
Toggle Summary Stereotaxis Receives FDA Clearance of Vdrive(TM) With V-Loop(TM) System
ST. LOUIS , Sept. 4, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has received 510(k) clearance by the Food and Drug Administration ( FDA ) to market its Vdrive™ Robotic Navigation System with V-Loop™ Variable Loop Catheter Manipulator in the U.S.
View HTML
Toggle Summary Stereotaxis Secures First Niobe(R) System Order in Japan
Establishes Japan Business Office to Manage Market Operations ST. LOUIS , Sept. 24, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has received the first commercial order for its Niobe® ES magnetic navigation system in Japan from a leading hospital in Osaka .
View HTML
Toggle Summary Stereotaxis to Report Third Quarter 2014 Financial Results on November 5, 2014
ST. LOUIS , Oct. 30, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will release financial results for its 2014 third quarter ended September 30, 2014 on Wednesday, November 5, 2014 after the close of the U.S. financial markets.
View HTML
Toggle Summary Stereotaxis Reports 2014 Third Quarter Financial Results
-Improves System Revenue 89% Sequentially from Second Quarter 2014- -Completes Five New Niobe® ES System Installations- -Secures First Niobe® ES System Order in Japan - -Achieves Record Low Operating Expenses of $7.7 Million - -Receives FDA Clearance of Vdrive® with V-Loop™ System- -Hosts
View HTML
Toggle Summary Stereotaxis Receives FDA Clearance of Vdrive(R) With V-CAS(TM) System Along With Regulatory Approval of Odyssey(R) System in Japan
ST. LOUIS , Jan. 5, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) announced today that it has received 510(k) clearance by the Food and Drug Administration ( FDA ) for its Vdrive® with V-CAS™ Catheter Advancement System in the U.S., representing the Company's third Vdrive system product
View HTML
Toggle Summary Stereotaxis Surpasses 75,000 Procedures With Remote Magnetic Navigation System
Company to Highlight Latest Advancements at International AF Symposium ST. LOUIS , Jan. 6, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS), a leading provider of innovative technologies for the treatment of cardiac arrhythmias, announced today that more than 75,000 patient cases have been
View HTML
Toggle Summary Tucson Medical Center and Stereotaxis Bring First Vdrive(R) With V-Loop(TM) System to U.S.
ST. LOUIS , Jan. 8, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, and Tucson Medical Center , Tucson, Arizona's locally governed nonprofit regional hospital since 1944, announced today that they have
View HTML
Toggle Summary Stereotaxis and Princess Grace Hospital Share Significant New Clinical Data for Remote Magnetic Ablation Procedures
ST. LOUIS , Jan. 13, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) and Princess Grace Hospital of Monaco today announced the results of a recent clinical study conducted in Europe , which represent significant findings in terms of the Stereotaxis remote magnetic navigation platform's
View HTML
Toggle Summary Stereotaxis to Report Fourth Quarter and Full Year 2014 Financial Results on February 25, 2015
ST. LOUIS , Feb. 18, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2014 fourth quarter and full year ended December 31, 2014 on Wednesday,
View HTML
Toggle Summary CHU de Saint-Etienne Launches Second Stereotaxis Lab
Becomes First Hospital in Europe to Operate Two Niobe(R) Systems for Clinical Procedures ST. LOUIS , Feb. 18, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS) and Centre Hospitalier Universitaire (CHU) of Saint-Étienne, France , today announced the installation of the hospital's second
View HTML
Toggle Summary Stereotaxis Reports 2014 Fourth Quarter and Full Year Financial Results
-Achieves First Quarterly Operating Income in Company History- -Increases Fourth Quarter Revenue 8% Year over Year and 10% Sequentially- -Reports Record Annual Recurring Revenue of $27.2 Million - -Reduces Annual Operating Loss to $(5.4) Million and Net Loss to $(5.2) Million , the Lowest Since
View HTML
Toggle Summary Florida Hospital First in U.S. to Use Stereotaxis Vdrive(R) Duo(TM) System to Control Multiple Diagnostic Devices
ST. LOUIS , March 27, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, and the Florida Hospital Cardiovascular Institute in Orlando, Fla. , today announced the first use of the Stereotaxis Vdrive Duo™
View HTML
Toggle Summary Stereotaxis Extends Silicon Valley Bank Credit Facility by Three Years
ST. LOUIS , March 30, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it has extended the maturity of its revolving credit facility with Silicon Valley Bank (SVB) by three years to
View HTML
Toggle Summary Stereotaxis to Report First Quarter 2015 Financial Results on May 6, 2015
ST. LOUIS , April 29, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq: STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 first quarter ended March 31, 2015 on Wednesday, May 6, 2015
View HTML
Toggle Summary Stereotaxis Elects Medical Device Industry Veteran Duane DeSisto to Board of Directors
ST. LOUIS , May 4, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the election of medical device industry veteran Duane DeSisto to its Board of Directors. Mr.
View HTML
Toggle Summary Stereotaxis Reports 2015 First Quarter Financial Results
- Total Revenue Increased 14% over Prior Year First Quarter - - System Revenue Increased 112% Year over Year - - Operating Loss Decreased 37% Year over Year - - Silicon Valley Bank Credit Facility Extended by Three Years - - Industry Veteran Duane DeSisto Appointed to Board of Directors - - Company
View HTML
Toggle Summary Stereotaxis to Present New Clinical Evidence and Product Innovations at Heart Rhythm 2015 in Boston
ST. LOUIS , May 13, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the 36 th Annual Heart Rhythm Society (HRS) Scientific Sessions, May 14-16, 2015 in Boston,
View HTML
Toggle Summary Stereotaxis to Present at Cantor Fitzgerald Inaugural Healthcare Conference in New York on July 8, 2015
ST. LOUIS , July 2, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that William C. Mills , CEO, and Martin C. Stammer , CFO, will present at the Cantor Fitzgerald Inaugural Healthcare
View HTML
Toggle Summary Takatsuki General Hospital Performs First Procedure With Stereotaxis Niobe(R) ES Technology in Japan
ST. LOUIS , July 8, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that the first procedure with its Niobe® ES magnetic navigation system has been performed in Japan . Dr.
View HTML
Toggle Summary Stereotaxis to Report Second Quarter 2015 Financial Results on August 4, 2015
ST. LOUIS , July 28, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 second quarter ended June 30, 2015 on Tuesday, August 4, 2015
View HTML
Toggle Summary Stereotaxis Reports 2015 Second Quarter Financial Results
- Total Revenue Increased 20% over Prior Year Second Quarter and 17% Year to Date - - Quarterly Operating Loss Decreased 25% Year over Year and 31% for the First Six Months Period - - First Niobe® ES Procedures Performed in Japan - - New Evidence of Clinical Advantages in Ventricular Tachycardia
View HTML
Toggle Summary Erasmus Medical Center Study Highlights Advantages of Stereotaxis Platform Compared to State-of-the-Art Manual Techniques in VT
ST. LOUIS , Aug. 10, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS) and Erasmus Medical Center in Rotterdam, The Netherlands today announced the results of a seven-year clinical study, which provides significant findings in terms of the Stereotaxis remote magnetic navigation platform's
View HTML
Toggle Summary Westmead Hospital Research Provides Significant Data Supporting the Ablation Effectiveness of Stereotaxis Magnetic Navigation
ST. LOUIS , Aug. 27, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS) and Westmead Hospital in Australia today announced findings of a recent study comparing the stability of a Niobe® remote magnetic navigation system catheter group and a manually controlled catheter group in a validated
View HTML
Toggle Summary Stereotaxis Awarded U.S. Patent Covering Transmission of Data for Odyssey(R) Solutions
ST. LOUIS , Sept. 1, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,111,016 to the Company entitled "Management of Live
View HTML
Toggle Summary Stereotaxis Announces Warrants Offering
ST. LOUIS , Sept. 4, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will conduct a registered offering of subscription warrants to the holders of its common shares, which will
View HTML
Toggle Summary Stereotaxis Announces Ex-Warrants Date of September 15, 2015 for Warrants Offering
ST. LOUIS , Sept. 15, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that the NASDAQ Capital Market has established September 15, 2015 as the "ex-warrants" date for its
View HTML
Toggle Summary U.S. Physician Surpasses 1,000 Procedures Using Stereotaxis Niobe(R) System
Dr. J. David Burkhardt of St. David's Medical Center First in U.S. to Reach Milestone ST. LOUIS , Sept. 21, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that J. David Burkhardt , M.D.
View HTML
Toggle Summary Stereotaxis Launches Vmotion Suite of Automation Features in U.S. Following FDA Clearance
Vmotion Features Enhance V-Sono(TM) System Capabilities ST. LOUIS , Sept. 23, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the first procedures performed in the U.S.
View HTML
Toggle Summary Stereotaxis Extends Warrants Offering Subscription Period
Company CEO and CFO Fully Exercise Subscription Warrants ST. LOUIS , Sept. 28, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced it is extending its registered offering of subscription
View HTML
Toggle Summary Stereotaxis Announces Results of Warrants Offering
ST. LOUIS , Oct. 08, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (“ Stereotaxis”) (NASDAQ:STXS) a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of its previously announced offering of subscription warrants to purchase shares of its
View HTML
Toggle Summary Stereotaxis Introduces Respiratory Compensation Feature for Remote Magnetic Navigation Procedures
ST. LOUIS , Oct. 12, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the worldwide launch of Respiratory Compensation, a new software feature of the Company’s Niobe ® remote magnetic
View HTML
Toggle Summary Stereotaxis to Report Third Quarter 2015 Financial Results on November 3, 2015
ST. LOUIS , Oct. 27, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 third quarter ended September 30, 2015 on Tuesday, November 3, 2015
View HTML
Toggle Summary Stereotaxis Reports 2015 Third Quarter Financial Results
-Total Quarterly Revenue Increased 5% Year over Year on Improved System and Recurring Revenues-  -Total Revenue for First Nine Months Increased 13% Year over Year to $28.5 Million -  -System Revenue for First Nine Months Increased 76% Year over Year to $8.2 Million -  -Operating Loss Decreased 23%
View HTML
Toggle Summary Multicenter Study Reveals Improved Long-Term Success Rates With Stereotaxis Technology in Ventricular Tachycardia 
ST. LOUIS , Nov. 17, 2015 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of an independent multicenter study on the procedural benefits and outcomes of patients undergoing
View HTML
Toggle Summary Stereotaxis Initiates Multi-Center Randomized Superiority Study on Ventricular Tachycardia Ablation Outcomes
Compares Magnetic Navigation to Manual Techniques for the Treatment of VT ST. LOUIS , Jan. 11, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it has initiated its first prospective,
View HTML
Toggle Summary Stereotaxis and Philips Extend Development Collaboration to Interface Latest Systems
ST. LOUIS and BEST, The Netherlands , Jan. 26, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS) today announced Stereotaxis and Philips have signed an addendum pursuant to their existing Development and Cooperation Agreement to facilitate development of a new interface between each
View HTML
Toggle Summary University Medical Center New Orleans Implements Stereotaxis Platform for Advanced Treatment of Cardiac Arrhythmias
ST. LOUIS , Feb. 01, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, and University Medical Center (UMC) New Orleans , the academic medical center of LCMC Health , today announced the first procedures
View HTML
Toggle Summary Stereotaxis to Report Fourth Quarter and Full Year 2015 Financial Results on February 22, 2016
ST. LOUIS , Feb. 08, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2015 fourth quarter and full year ended December 31, 2015 on Monday,
View HTML
Toggle Summary Stereotaxis to Participate at BTIG’s 2016 MedTech Conference
ST. LOUIS , Feb. 16, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that William C. Mills , CEO, and Martin C. Stammer , CFO, will participate in BTIG’s 2016 MedTech Conference on
View HTML
Toggle Summary Stereotaxis Reports 2015 Fourth Quarter and Full Year Financial Results
New capital orders of $5.1 million in the fourth quarter, including two Niobe ® ES system orders in Japan Fourth quarter free cash flow of $1.6 million , driving a 71% reduction in full year cash burn compared to 2014 Ventricular Tachycardia procedures in the fourth quarter grew 28% year over year,
View HTML
Toggle Summary Journal of Cardiovascular Electrophysiology Publishes Special Issue Dedicated to Stereotaxis Technology
ST. LOUIS , March 11, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the Journal of Cardiovascular Electrophysiology ( http://onlinelibrary.wiley.com/journal/10.1111/ (ISSN)1540-8167
View HTML
Toggle Summary Centre Hospitalier Régional Universitaire de Nancy Strengthens Leadership in Cardiac Rhythm Management through Stereotaxis Technology
ST. LOUIS , March 18, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the first patients treated with the Niobe ® ES remote magnetic navigation system at the Centre Hospitalier Régional
View HTML
Toggle Summary Stereotaxis Completes Patient Enrollment for Niobe® System’s Post-Market Surveillance in Japan
Takatsuki Hospital Reaches Milestone of 120 Patients Treated with Niobe System     ST. LOUIS , March 30, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that Takatsuki General Hospital , a
View HTML
Toggle Summary U.S. Hospital Surpasses 1,000 Procedures using Stereotaxis Niobe® System
Saint Francis Leads New England in Treatment with Remote Magnetic Navigation     ST. LOUIS , April 04, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the Hoffman Heart and Vascular
View HTML
Toggle Summary Lund University Hospital Study Validates Improved Long-Term Clinical Outcomes Using Stereotaxis Technology
ST. LOUIS , April 07, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of a long-term follow-up study on the efficacy of the Stereotaxis Niobe ® ES magnetic navigation system
View HTML
Toggle Summary Stereotaxis Awarded U.S. Patent for Vmotion Spotlight Automation Feature of Vdrive® Robotic Navigation System
ST. LOUIS , April 29, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,314,222 titled, “Operation of a Remote Medical
View HTML
Toggle Summary Stereotaxis to Report First Quarter 2016 Financial Results on May 9, 2016
ST. LOUIS , May 02, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2016 first quarter ended March 31, 2016 on Monday, May 9, 2016 after the
View HTML
Toggle Summary Stereotaxis to Highlight New Clinical Results and Automation Enhancements at Heart Rhythm 2016 in San Francisco May 4-7
ST. LOUIS , May 04, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the 37 th Annual Heart Rhythm Society (HRS) Scientific Sessions, May 4-7, 2016 in San
View HTML
Toggle Summary Stereotaxis Reports 2016 First Quarter Financial Results
Ventricular tachycardia procedures increased 27% year over year, representing the third consecutive quarter of 20%+ volume growth Fourth Niobe ® system shipped to Japan Patient enrollment completed for Niobe ® post-market surveillance in Japan Clinical literature expands to more than 260
View HTML
Toggle Summary Paracelsus Medical University Clinical Study on Stereotaxis Technology Benefits Recognized at European Cardiac Arrhythmia Society Congress
ST. LOUIS , June 01, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the results of a retrospective study conducted at Paracelsus Medical University in Nuremberg, Germany , which showed
View HTML
Toggle Summary Stereotaxis to Share its Latest Technology Advancements and Clinical Evidence at Cardiostim 2016 in Nice, France June 8-11
ST. LOUIS , June 07, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that it will share the latest innovations to its Niobe ® ES magnetic navigation system and supporting clinical evidence
View HTML
Toggle Summary Saint Alphonsus Physician Surpasses Procedure Milestone Using Stereotaxis Niobe® ES System
ST. LOUIS , June 14, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, and Saint Alphonsus Health System in Idaho today announced that Dr. Margot Vloka has completed more than 500 cardiac ablation
View HTML
Toggle Summary Stereotaxis Niobe® ES System Installed at Texas Children’s Hospital
First pediatric institution in U.S. to offer magnetic navigation technology for cardiac ablation ST. LOUIS , July 08, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that Texas Children’s
View HTML
Toggle Summary University of Chicago Medicine Creating High-Tech Arrhythmia Technology Suite with Stereotaxis Niobe® ES System
ST. LOUIS , July 13, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that the University of Chicago Medicine will implement the Company’s Niobe ® ES remote magnetic navigation system as
View HTML
Toggle Summary Stereotaxis Releases Second Generation V-CAS Deflect™ System in Europe
Catheter Advancement System Offers Remote Control of Proprietary Deflectable Sheath during Cardiac Ablation Procedures ST. LOUIS , July 26, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced
View HTML
Toggle Summary Stereotaxis to Report Second Quarter 2016 Financial Results on August 9, 2016
ST. LOUIS , Aug. 02, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2016 second quarter ended June 30, 2016 on Tuesday, August 9, 2016 after
View HTML
Toggle Summary Stereotaxis Common Stock to Begin Trading on OTCQX on August 4, 2016
ST. LOUIS , Aug. 03, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NASDAQ:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, announced today that its shares of common stock will be eligible for trading on the OTCQX ® Best Market, effective with the open of
View HTML
Toggle Summary Stereotaxis Reports 2016 Second Quarter Financial Results
Ventricular tachycardia procedures increased 24% year over year, representing the 10th consecutive quarter of year-over-year volume growth Three Niobe ® system installations completed, including the second installation in Japan Enhanced V-CAS Deflect ™ catheter advancement system released in Europe
View HTML
Toggle Summary Stereotaxis Completes Niobe® System Installation at Kakogawa Hospital
New Hospital Represents Second Niobe Site in Japan ST. LOUIS , Aug. 09, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced the launch of its Niobe ® remote magnetic navigation system at
View HTML
Toggle Summary Stereotaxis Announces Multiple Positive Strategic Updates
- $24 Million Equity Investment - - Recruitment of Highly Experienced Board Members - - Retirement of Debt at Significant Discount - ST. LOUIS , Sept. 27, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac
View HTML
Toggle Summary Stereotaxis Completes Private Placement of $24 Million
ST. LOUIS , Sept. 29, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has closed its previously announced private placement equity financing with a select group of
View HTML
Toggle Summary UCLA Medical Center Implements Latest Stereotaxis Technology with Upgrade to Niobe® ES Remote Magnetic Navigation System
ST. LOUIS , Oct. 05, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Ronald Reagan UCLA Medical Center in Los Angeles has installed the latest Niobe ® ES remote magnetic
View HTML
Toggle Summary Stereotaxis Awarded Patent in China for Vdrive® System with V-Loop™ Manipulator
ST. LOUIS , Oct. 13, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that the State Intellectual Property Office of the People’s Republic of China has awarded a patent protecting
View HTML
Toggle Summary Stereotaxis Technologies to be Highlighted at Society for Cardiac Robotic Navigation’s Inaugural Meeting in Amsterdam
ST. LOUIS , Oct. 18, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that its magnetic and robotic navigation systems will be represented at the inaugural meeting of the Society for
View HTML
Toggle Summary Robert Wood Johnson University Hospital Physician Surpasses 500 Procedures Using Stereotaxis Niobe® System
ST. LOUIS , Oct. 25, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, and Robert Wood Johnson University Hospital (RWJUH), a Cardiovascular Center of Excellence and the principal teaching hospital
View HTML
Toggle Summary Stereotaxis to Report Third Quarter 2016 Financial Results on November 7, 2016
ST. LOUIS , Nov. 02, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2016 third quarter ended September 30, 2016 on Monday, November
View HTML
Toggle Summary Stereotaxis Reports 2016 Third Quarter Financial Results
Completed $24 million private placement equity financing Retired all outstanding debt at significant discount Appointed three board members with extensive medical device experience Shipped fifth Niobe ® ES system to Japan Grew ventricular tachycardia procedures by 25% and total procedures by 3%
View HTML
Toggle Summary Stereotaxis Launches Interface between Niobe® ES System and Philips’ State-of-the-art X-ray System
ST. LOUIS , Dec. 14, 2016 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the release of an interface between its remote magnetic navigation system for electrophysiology (EP) procedures
View HTML
Toggle Summary Stereotaxis Announces Management Transition and 2016 Financial Results
- Resignation of William C. Mills as CEO and Chairman - - Appointment of David Fischel as Acting CEO and Chairman - - Appointment of Nathan Fischel , MD as Director - - Preliminary Unaudited Fourth Quarter and Full Year 2016 Financial Results - ST. LOUIS , Feb.
View HTML
Toggle Summary Montreal Heart Institute Implements Stereotaxis Technologies
Internationally Recognized Cardiology Center Utilizing Niobe® ES System for Cardiac Ablation ST. LOUIS , Feb. 16, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, and the Montreal Heart Institute
View HTML
Toggle Summary First Site in Japan to Install Stereotaxis Technology Completes 250 Procedures
Takatsuki Hospital Achieves Significant Levels of Success and Safety for Ablation Patients ST. LOUIS , Feb. 23, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc.  (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Takatsuki
View HTML
Toggle Summary Stereotaxis to Present at 29th Annual ROTH Conference
ST. LOUIS , March 07, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel , Chairman and Acting Chief Executive Officer, is scheduled to present at the 29th Annual
View HTML
Toggle Summary Clinical Study Validates Efficiencies of Stereotaxis Niobe® ES System Compared to Niobe II System
ST. LOUIS , March 14, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported results of a study conducted at Centre Hospitalier Universitaire (CHU) of Saint-Étienne, France , which
View HTML
Toggle Summary Stereotaxis’ Leadership in Robotic Cardiac Ablation to be Showcased at Heart Rhythm 2017 and First Annual Meeting of Society for Cardiac Robotic Navigation (Americas)
ST. LOUIS , April 25, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the annual Heart Rhythm Society (HRS) Scientific Sessions at McCormick Place in
View HTML
Toggle Summary Stereotaxis to Report First Quarter 2017 Financial Results on May 8, 2017
ST. LOUIS , April 27, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 first quarter ended March 31, 2017 on Monday, May 8, 2017
View HTML
Toggle Summary Stereotaxis Reports 2017 First Quarter Financial Results
Procedures stable with gain in ventricular and decline in atrial procedures System sales at nadir; expect increase in latter half of 2017 from current initiatives Clinical focus on helping physicians build successful robotic practices Development focus on innovation of all aspects of robotic
View HTML
Toggle Summary Stereotaxis Launches the e-Contact™ Module in Europe
New Technology will be Showcased at EHRA EUROPACE-CARDIOSTIM 2017 ST. LOUIS , June 15, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the European launch of the e-Contact™ module.
View HTML
Toggle Summary Stereotaxis Receives Second Odyssey Vision™ System Orders from Two Leading Heart Hospitals
ST. LOUIS , July 11, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has secured second Odyssey Vision ™ system orders from McLaren Bay Region Hospital in Michigan and
View HTML
Toggle Summary Princess Grace Hospital Publishes Data Demonstrating More Rapid Transmural Lesion Formation Utilizing Stereotaxis Robotic Technology
ST. LOUIS , July 25, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS) and Princess Grace Hospital in Monaco today announced the publication of a study comparing the speed of lesion formation of magnetic catheters using the Niobe ® system to manually controlled contact force catheters.
View HTML
Toggle Summary Stereotaxis to Report Second Quarter 2017 Financial Results on August 10, 2017
ST. LOUIS , Aug. 03, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 second quarter ended June 30, 2017 on Thursday, August 10,
View HTML
Toggle Summary Stereotaxis Reports Second Quarter 2017 Financial Results
Stable recurring revenue and 2% year-over-year growth in global procedures Reduced operating expenses and operating loss Launch of e-Contact™ module in EU and progress in development of strategic innovation plans Reaffirming 2017 expectations Conference call today at 10:00 a.m. Eastern Time ST.
View HTML
Toggle Summary Research Finds that Stereotaxis Robotic Technology Provides Significant Advantages in Treatment of Ventricular Tachycardia Compared to Manual Techniques
ST. LOUIS , Aug. 14, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced the results of an independent meta-analysis of studies reporting the comparative safety, efficacy, and efficiency of
View HTML
Toggle Summary One Hundred Thousand Procedure Milestone Achieved by Stereotaxis’ Robotic Technology
ST. LOUIS , Aug. 28, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS) a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that 100,000 procedures have been performed using its Niobe ® magnetic navigation system.
View HTML
Toggle Summary Stereotaxis to Attend Asia Pacific Heart Rhythm Society Conference and Announces Japan Procedure Milestone
Continues to Grow Utilization and Enthusiasm for Robotic Technologies in Asia Pacific Market ST. LOUIS , Sept. 11, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that physicians at
View HTML
Toggle Summary Stereotaxis to Report Third Quarter 2017 Financial Results on November 9, 2017
ST. LOUIS , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 third quarter ended September 30, 2017 on Thursday, November
View HTML
Toggle Summary Stereotaxis Reports Third Quarter 2017 Financial Results
3% year-over-year growth in recurring revenue and 2% year-over-year growth in global procedures Reduced operating expenses leads to small quarterly operating profit Substantial progress on strategic innovation plans Scientific publication demonstrates significant clinical advantages of Stereotaxis
View HTML
Toggle Summary Stereotaxis to Present at 29th Annual Piper Jaffray Healthcare Conference
ST. LOUIS , Nov. 20, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel , Chairman and Chief Executive Officer, is scheduled to present at the 29th Annual Piper
View HTML
Toggle Summary Stereotaxis Receives Regulatory Approval of e-Contact™ Module in Canada
First Procedures Performed at Toronto’s Sunnybrook Health Sciences Centre ST. LOUIS , Dec. 05, 2017 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it has received regulatory
View HTML
Toggle Summary Stereotaxis Reports Preliminary Fourth Quarter 2017 Revenue Results
Revenue of $7.6 million for the fourth quarter and $31.2 million for the full year 2017 Fourth quarter year-over-year revenue growth of 4% and procedure growth of 5% ST. LOUIS , Jan. 08, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies
View HTML
Toggle Summary European Heart Rhythm Association Highlights Occupational Risk of Radiation Exposure in Electrophysiology Procedures
Stereotaxis technology included in recommendations to reduce fluoroscopy exposure and described as allowing “near zero exposure” to electrophysiologists Clinical data demonstrates significant reduction in radiation exposure for patients undergoing cardiac ablation procedures with Stereotaxis
View HTML
Toggle Summary Stereotaxis to Report Fourth Quarter and Full Year 2017 Financial Results on March 6, 2018
ST. LOUIS , March 02, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2017 fourth quarter and full year ended December 31, 2017 on
View HTML
Toggle Summary Stereotaxis Announces $10.0 Million Non-Dilutive Financing from Early Warrant Exercise
Enables continued execution of innovation and commercial initiatives Non-dilutive to shareholders Long term lock-up agreement on exercised warrants Represents necessary first step on path to relist on NASDAQ ST. LOUIS , March 06, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc.
View HTML
Toggle Summary Stereotaxis Reports 2017 Fourth Quarter and Full Year Financial Results
7% year-over-year growth in fourth quarter global procedures and recurring revenue Substantial progress in delineating and initiating strategic innovation plans Increasing quantity and quality of peer-reviewed clinical validation Strong financial position to reach profitability without the need for
View HTML
Toggle Summary Stereotaxis Announces Expanded European Labeling for Navigation in the Pericardial Space
ST. LOUIS , April 11, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that navigation in the pericardial space has been added to the CE Mark of the Niobe ® magnetic navigation
View HTML
Toggle Summary Stereotaxis Announces Publication of Clinical Research Supplement Highlighting Robotic Navigation for Cardiac Arrhythmias
ST. LOUIS , May 01, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that the Society for Cardiac Robotic Navigation (SCRN) has published a supplement in the European Journal of
View HTML
Toggle Summary Stereotaxis and Acutus Medical Announce Strategic Collaboration
Formal testing supports joint use of the two systems Positive initial clinical experience demonstrates additive benefits of technologies Commitment to robust integration of technologies to enhance ease-of-use and lab efficiency ST. LOUIS and CARLSBAD, Calif., May 03, 2018 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary Stereotaxis to Report First Quarter 2018 Financial Results on May 14, 2018
ST. LOUIS , May 04, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 first quarter ended March 31, 2018 on Monday, May 14, 2018
View HTML
Toggle Summary Stereotaxis to Highlight Unique Advantages of Robotic Cardiac Ablation at Heart Rhythm 2018
ST. LOUIS , May 04, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will participate in the annual Heart Rhythm Society (HRS) Scientific Sessions at the Boston Convention
View HTML
Toggle Summary Stereotaxis Reports 2018 First Quarter Financial Results
3% year-over-year growth in recurring revenue Continued progress on strategic innovation initiatives; collaboration with Acutus Medical Increasing quantity and quality of peer-reviewed clinical validation Strong financial position to reach profitability without the need for additional financings
View HTML
Toggle Summary Stereotaxis to Present at 8th Annual LD Micro Invitational
ST. LOUIS , May 22, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel , Chairman and Chief Executive Officer, is scheduled to present at the 8th Annual LD Micro
View HTML
Toggle Summary Stereotaxis Announces Changes to its Board of Directors
ST. LOUIS , June 04, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the appointment of Ross B. Levin to its board of directors. Mr.
View HTML
Toggle Summary Stereotaxis and Johnson & Johnson’s Biosense Webster Extend Development Alliance and Supply Agreement
ST. LOUIS , June 25, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it has entered into an amendment to the long-term Development Alliance and Supply Agreement with Johnson
View HTML
Toggle Summary Stereotaxis to Report Second Quarter 2018 Financial Results on August 7, 2018
ST. LOUIS , July 31, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 second quarter ended June 30, 2018 on Tuesday, August 7,
View HTML
Toggle Summary Stereotaxis Reports 2018 Second Quarter Financial Results
Progress on strategic internal innovation and external collaborations Continued growth in recurring revenue Positive cash flow from operations Reaffirming 2018 expectations Conference call today at 10:00 a.m. Eastern Time ST. LOUIS , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc.
View HTML
Toggle Summary Stereotaxis to Present at OTCQX Virtual Investor Conference for Domestic Companies
ST. LOUIS, Mo. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will present at the OTCQX Virtual Investor Conference for Domestic Companies .
View HTML
Toggle Summary Stereotaxis to Report Third Quarter 2018 Financial Results on November 12, 2018
ST. LOUIS , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 third quarter ended September 30, 2018 on Monday,
View HTML
Toggle Summary Stereotaxis Reports 2018 Third Quarter Financial Results
Continued progress on strategic innovation initiatives; expect to showcase in 1H 2019 4% recurring revenue growth; reaffirming 2018 record recurring revenue expectations Conference call today at 10:00 a.m. Eastern Time ST. LOUIS , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc.
View HTML
Toggle Summary Stereotaxis to Present at the 11th Annual LD Micro Main Event Investor Conference
ST. LOUIS , Nov. 26, 2018 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel , Chairman and Chief Executive Officer, is scheduled to present at the 11 th Annual LD
View HTML
Toggle Summary Stereotaxis Announces Partnership with Kansas City Heart Rhythm Institute to Bring New Treatment to Arrhythmia Patients
ST. LOUIS , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias announced today a partnership with Kansas City Heart Rhythm Institute to bring new and cutting-edge treatments to arrhythmia
View HTML
Toggle Summary Stereotaxis to Participate in BTIG Healthcare Investor Conference
ST. LOUIS , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel , Chairman and Chief Executive Officer, is scheduled to participate in the BTIG Healthcare
View HTML
Toggle Summary Stereotaxis to Report Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019
ST. LOUIS , March 04, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 fourth quarter and full year ended December 31, 2018 on
View HTML
Toggle Summary Stereotaxis Reports 2018 Full Year Financial Results
Record high annual recurring revenue of $27.8 million ; 3% annual growth Positive annual net income for the first time in Company history despite significantly increased R&D investments Innovation initiatives to be showcased in May at Heart Rhythm Society meeting Strong financial position to reach
View HTML
Toggle Summary Stereotaxis and Acutus Medical Combine Robotic Precision and High-Resolution Imaging to Treat Arrhythmias in First Integrated Procedures
First patients successfully treated with robust integration of technologies Integrated technologies now commercially available ST. LOUIS and CARLSBAD, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Stereotaxis  (OTCQX: STXS) and Acutus Medical today announced the first patients have been successfully
View HTML
Toggle Summary Stereotaxis to Highlight Latest Techniques for Performing Robotic Ablations at European Heart Rhythm Association Annual Congress March 17-19
ST. LOUIS , March 15, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it will be attending the European Heart Rhythm Association (EHRA) Annual Congress from March 17-19 in
View HTML
Toggle Summary Stereotaxis to Showcase Innovation and Technology at Heart Rhythm 2019 and Report First Quarter 2019 Financial Results on May 8-9, 2019
Innovation Update Presentation on the Evening of May 8 at Heart Rhythm Society Innovation Update Press Releases and First Quarter Financial Release Issued Prior to the Market Open on May 9 First Quarter Investor Conference Call on May 9 at 9:00 a.m. Eastern Time ST.
View HTML
Toggle Summary Stereotaxis Reports 2019 First Quarter Financial & Operational Results
ST. LOUIS , May 09, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the first quarter ended March 31, 2019 . In separate press releases issued concurrently with
View HTML
Toggle Summary Stereotaxis and Osypka Enter Strategic Collaboration to Advance Robotic Catheter Technology
  Development of next generation robotically-navigated magnetic ablation catheter fully owned by Stereotaxis   Catheter designed to enhance patient care, improve therapy delivery, simplify catheter navigation, and strengthen commitment to open ecosystem   Entered into additional business agreements
View HTML
Toggle Summary Stereotaxis Announces Next Generation Robotic Magnetic Navigation System and Imaging System
Innovative robotic surgery system, Stereotaxis Genesis™ RMN, enriches robotic magnetic navigation with increased efficiency, reduced size, and enhanced lab experience Genesis RMN System to be available in combination with Stereotaxis Imaging Model S, a next-generation x-ray system offered as part
View HTML
Toggle Summary Stereotaxis to Present at 9th Annual LD Micro Invitational
ST. LOUIS , May 29, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel , Chairman and Chief Executive Officer, is scheduled to present at the 9th Annual LD Micro
View HTML
Toggle Summary Stereotaxis Announces the First Graduating Class of the Robotic Electrophysiology Fellows Program
ST. LOUIS , June 18, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the first graduating class from its Robotic Electrophysiology Fellows Program.
View HTML
Toggle Summary Society for Cardiac Robotic Navigation to Showcase Stereotaxis Clinical Value & Technology
ST. LOUIS , July 31, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will participate in the Society for Cardiac Robotic Navigation’s 4th Annual Meeting , which will take place
View HTML
Toggle Summary Stereotaxis to Report Second Quarter 2019 Financial Results on August 8, 2019
ST. LOUIS , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2019 second quarter ended June 30, 2019 on Thursday, August 8,
View HTML
Toggle Summary Stereotaxis Announces $25 Million Private Placement
ST. LOUIS , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it has entered into a securities purchase agreement with select institutional investors for a $25 million
View HTML
Toggle Summary Stereotaxis Reports 2019 Second Quarter Financial Results
ST. LOUIS , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the second quarter ended June 30, 2019 . In a separate press release issued concurrently with
View HTML
Toggle Summary Stereotaxis Announces Uplisting to NYSE American
ST. LOUIS , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that its common stock has been approved for listing on the NYSE American.
View HTML
Toggle Summary Stereotaxis Announces CFO Transition
ST. LOUIS, Mo. , Sept. 16, 2019 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE American: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that Kimberly Peery has been appointed Stereotaxis Chief Financial Officer, effective October 1, 2019
View HTML
© Copyright Stereotaxis 2019